933 related articles for article (PubMed ID: 8281661)
1. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
[TBL] [Abstract][Full Text] [Related]
2. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
Mousa SA; DeGrado WF; Mu DX; Kapil RP; Lucchesi BR; Reilly TM
Circulation; 1996 Feb; 93(3):537-43. PubMed ID: 8565173
[TBL] [Abstract][Full Text] [Related]
3. Intravenous antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs.
Mousa SA; Flint S; Lorelli W; Hassell S; Bozarth J; De Grado W; Reilly TM
Thromb Res; 1994 Oct; 76(2):109-19. PubMed ID: 7863463
[TBL] [Abstract][Full Text] [Related]
4. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.
Mousa SA; Kapil R; Mu DX
Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2535-41. PubMed ID: 10521384
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis.
Rote WE; Davis JH; Mousa SA; Reilly TM; Lucchesi BR
J Cardiovasc Pharmacol; 1994 Apr; 23(4):681-9. PubMed ID: 7516023
[TBL] [Abstract][Full Text] [Related]
6. Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist.
Mousa SA; Forsythe M; Wityak J; Bozarth J; Mu DX
J Cardiovasc Pharmacol; 1998 Mar; 31(3):441-8. PubMed ID: 9514190
[TBL] [Abstract][Full Text] [Related]
7. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM
Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
[TBL] [Abstract][Full Text] [Related]
8. Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonist in dogs.
Mousa SA; Mu DX; Lucchesi BR
Stroke; 1997 Apr; 28(4):830-5; discussion 835-6. PubMed ID: 9099204
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
11. Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.
Mousa SA; Olson RE; Bozarth JM; Lorelli W; Forsythe MS; Racanelli A; Gibbs S; Schlingman K; Bozarth T; Kapil R; Wityak J; Sielecki TM; Wexler RR; Thoolen MJ; Slee A; Reilly TM; Anderson PS; Friedman PA
J Cardiovasc Pharmacol; 1998 Aug; 32(2):169-76. PubMed ID: 9700976
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis.
Collen D; Lu HR; Stassen JM; Vreys I; Yasuda T; Bunting S; Gold HK
Thromb Haemost; 1994 Jan; 71(1):95-102. PubMed ID: 8165652
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effect of Z4A5 on coronary thrombosis in a canine model of acute unstable angina.
Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Shen XL; Wang YL; Zang WJ; Wang B
Br J Pharmacol; 2013 Jun; 169(4):848-59. PubMed ID: 23083032
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model.
Imura Y; Stassen JM; Bunting S; Stockmans F; Collen D
Blood; 1992 Sep; 80(5):1247-53. PubMed ID: 1515641
[TBL] [Abstract][Full Text] [Related]
15. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
Huang J; Rebello SS; Faul JD; Lucchesi BR
Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis.
Willette RN; Sauermelch CF; Rycyna R; Sarkar S; Feuerstein GZ; Nichols AJ; Ohlstein EH
Stroke; 1992 May; 23(5):703-11. PubMed ID: 1605806
[TBL] [Abstract][Full Text] [Related]
17. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
[TBL] [Abstract][Full Text] [Related]
18. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog.
Rebello SS; Driscoll EM; Lucchesi BR
Stroke; 1997 Sep; 28(9):1789-96. PubMed ID: 9303027
[TBL] [Abstract][Full Text] [Related]
19. Intranasal antiplatelet/antithrombotic efficacy of a novel platelet GPIIB/IIIA receptor antagonist DMP755.
Mousa SA; Mu DX; Hussain MA
Thromb Res; 1998 Nov; 92(3):115-24. PubMed ID: 9806363
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
